Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Inclusion Criteria: * Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder * Recurrent or progressive low-grade B-cell lymphoma with at least one prior chemotherapy regimen (may have included monoclonal antibody) * Relapsed intermediate-grade or high-grade B-cell lymphoma or B-lineage acute lymphoblastic leukemia and patient not a candidate for, refused, or failed prior hematopoietic stem cell transplantation * No chronic lymphocytic leukemia or lymphoma with more than 5,000/mm3circulating lymphoma cells * Measurable or evaluable disease * Must have failed standard curative therapy * No CNS or leptomeningeal metastasis * Performance status - Karnofsky 70-100% * Performance status - ECOG 0-1 * At least 4 months * Absolute neutrophil count at least 1,000/mm\^3 * Hemoglobin at least 10 g/dL (transfusion allowed) * Platelet count at least 50,000/mm\^3 * AST no greater than upper limit of normal (ULN) * Bilirubin no greater than 1.5 times ULN * Hepatitis B surface antigen negative * Creatinine no greater than ULN * No prior unstable coronary artery disease * No New York Heart Association class III or IV congestive heart failure * DLCO and FEV1 at least 50% of predicted * HIV negative * No other concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix * No infection requiring IV antibiotic therapy within the past 4 weeks * No other major illness that would preclude study * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * See Disease Characteristics * Prior antibody therapy allowed * Prior interleukin-2 or interferon alfa allowed * See Disease Characteristics * At least 4 weeks since prior chemotherapy * At least 4 weeks since prior systemic corticosteroids * At least 4 weeks since prior radiotherapy * At least 4 weeks since prior surgery